Giovanna Finocchiaro

Rozzano, 20089, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications

PIK3CA Alterations in NSCLC: Clinical Characteristics of a "Neglected" Population of Oncogene-Addicted Patients.

PIK3CA Alterations in NSCLC: Clinical Characteristics of a "Neglected" Population of Oncogene-Addicted Patients.

Journal: Biomedicines
Published: December 18, 2025

Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial.

Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial.

Journal: Cancer treatment and research communications
Published: July 22, 2025

Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events.

Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events.

Journal: Journal for immunotherapy of cancer
Published: March 07, 2025

Retreatment with Immune Checkpoint Inhibitors in the New Scenario of Immunotherapy in Non-Small Cell Lung Cancer.

Retreatment with Immune Checkpoint Inhibitors in the New Scenario of Immunotherapy in Non-Small Cell Lung Cancer.

Journal: Cancers
Published: March 28, 2024

Response to first-line pembrolizumab in metastatic KRAS-mutated non-small-cell lung cancer.

Response to first-line pembrolizumab in metastatic KRAS-mutated non-small-cell lung cancer.

Journal: Future oncology (London, England)
Published: March 06, 2024

RORγ Bridges Cancer-Driven Lipid Dysmetabolism and Myeloid Immunosuppression.

RORγ Bridges Cancer-Driven Lipid Dysmetabolism and Myeloid Immunosuppression.

Journal: Cancer discovery
Published: February 12, 2024

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.

Journal: The Lancet. Oncology
Published: January 19, 2024

The Smokers Health Multiple ACtions (SMAC-1) Trial: Study Design and Results of the Baseline Round.

The Smokers Health Multiple ACtions (SMAC-1) Trial: Study Design and Results of the Baseline Round.

Journal: Cancers
Published: November 12, 2023

The Era of Immunotherapy in Small-Cell Lung Cancer: More Shadows Than Light?

The Era of Immunotherapy in Small-Cell Lung Cancer: More Shadows Than Light?

Journal: Cancers
Published: September 26, 2023

Management of patients with extensive small-cell lung cancer in the immunotherapy era: An Italian consensus through a Delphi approach.

Management of patients with extensive small-cell lung cancer in the immunotherapy era: An Italian consensus through a Delphi approach.

Journal: Critical reviews in oncology/hematology
Published: January 30, 2023

Current treatment approaches for brain metastases in ALK/ROS1/NTRK-positive non-small-cell lung cancer.

Current treatment approaches for brain metastases in ALK/ROS1/NTRK-positive non-small-cell lung cancer.

Journal: Expert review of anticancer therapy
Published: December 22, 2022

Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.

Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.

Journal: Nature medicine
Published: October 31, 2022
Showing 1-12 of 35

Last Updated: 09/26/2026